Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Life Sciences Index Present Pharma Integrates 2013

Published: Monday, April 08, 2013
Last Updated: Monday, April 08, 2013
Bookmark and Share
Strategically transforming Pharma business relationships.

Date/Venue
•    Pharma Integrates 2013 will be held on Tuesday 26th and Wednesday 27th November at the Riverbank Park Plaza, London. Further details available at www.lifesciencesindex.com.

Format
•    Following the success of the inaugural Pharma Integrates 2012, PI 2013 will retain the one and a half day conference format. Chairman Professor Trevor Jones CBE, Director Allergan & President of Sigma Tau Pharmaceuticals will be opening the half day series of keynotes and plenary panel discussions. The second day will include multiple tracks, with the majority of the sessions being interactive panel discussions to stimulate information exchange and organic discussion.

Theme
•    The overarching theme of Pharma Integrates is ‘Strategically transforming Pharma business relationships’,  with presentations and panel discussions addressing key industry issues from both an early and late product life cycle perspective. In 2013, we will examine how strategic relationships are evolving and increasingly becoming a source of mutual competitive advantage. Further how such collaborations are supporting innovation, productivity, differentiation and profitable growth. Topics to be addressed will include Risk Sharing, Biosimilars, Pricing, Partnering, Open Innovation and Pharma Intellectual Property.

•    Further details of Day One and Day Two Agenda available here: http://www.lifesciencesindex.com/pharma-integrates-2013-agenda

What to expect from Pharma Integrates 2013

•    Unique panel discussion format ensuring the ultimate interactive experience.

•    Blockbuster topics that straddle a complementary profile of industry stakeholders.

•    Strategically led content dedicated to senior level strategists

•    Unrivalled networking opportunities with champagne reception, luncheon and extended breaks throughout the conference timetable.

Attendee Feedback from Pharma Integrates 2012

“Relevant, good speakers, right size. Made many new contacts – thanks!” Neil Baker, Pfizer.

“Nothing similar in the EU. Panel discussion approach very successful.” Laura Walsh, 3M.

“The event attracted high level delegates and decision makers and was very informal. Good presentations, very entertaining.” Heather Brunyee, Wockhardt.

“Enjoyed the level of attendees, good mix of stakeholders- all with a passion to improve the industry. We now need to deliver!” David Tudbury, Catalent.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,900+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
BioCision Forms MedCision
The new company will focus on technologies for the management and automation of vital clinical processes.
First New HIV Vaccine Study for Seven Years Begins
South Africa hosts historic clinical trial of experimental HIV vaccine aiming to safely prevent HIV infection.
Study to Assess Shorter-Duration Antibiotics in Children
Physicians plan a clinical trial to evaluate whether short course anti-biotics are effective at treating CAP in children.
Cancer Gene Predicts Treatment Response in Leukaemia
Study indicates the patients suffering from a lethal for of acute myeloid leukemia may live longer when receiving milder chemotherapy drugs.
Injectable Biologic Therapy Reduces Triglycerides
Study finds first-of-its-kind therapy promising for patients with high triglycerides, cholesterol.
Testing Zika Vaccine in Humans Begins
The first of five planned clinical trials to test ZPIV vaccine in humans has begun.
Combination Therapy Improved Chemoresistance in Ovarian Cancer
The study demonstrates how an existing class of targeted therapies could be used to potentiate the tumor suppression induced by cisplatin.
Gene Therapy for Blistering Skin Disease Shows Promise
Grafting genetically altered skin onto patients’ chronic wounds marks the first time skin-based gene therapy has been demonstrated to be safe and effective in humans.
Alzheimer’s Treatment Moves a Step Closer
Merck scientists have reported the discovery of verubecestat, a structurally unique, orally bioavailable small molecule that has been shown to target the most visible sign of the disease in the brain.
Lynparza Phase III Progression-Free Survival Benefit
AstraZeneca announces results from Phase III SOLO-2 trial designed to determine the efficacy of Lynparza as a monotherapy for ovarian cancer.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!